[Invasive pulmonary aspergillosis in children with hepatic transplant: a survivor]

Verónica Botero1, Víctor H García1, Alejandro Delgado1

  • 1Departamento de Trasplantes y Centro de Investigaciones Clínicas, Fundación Valle del Lili, Colombia.

Abstract

Insights

Invasive Pulmonary Aspergillosis (IPA) is a severe complication in liver transplant recipients, often leading to high mortality. Early diagnosis and antifungal treatment are crucial for improving outcomes in these immunocompromised patients.

Area of Science:

  • Medical Mycology
  • Transplant Infectious Diseases
  • Critical Care Medicine

Background:

  • Liver transplant recipients are highly susceptible to opportunistic fungal infections.
  • Aspergillus species cause significant morbidity and mortality in this population, with up to 90% mortality rates.
  • Infections often manifest within months post-transplant, with opportunistic agents implicated in 10% of cases.

Observation:

  • A case of an 11-month-old infant with a history of liver transplant for biliary atresia is presented.
  • The patient developed severe pneumonia requiring mechanical ventilation.
  • Diagnostic evaluation included bronchoalveolar lavage.

Findings:

  • Bronchoalveolar lavage revealed elevated galactomannan levels.
  • Fungal cultures confirmed the presence of Aspergillus fumigatus.
  • The patient was diagnosed with Invasive Pulmonary Aspergillosis (IPA).

Implications:

  • Early suspicion and diagnosis of IPA are critical in liver transplant patients.
  • Prompt initiation of antifungal therapy can significantly reduce the high mortality associated with IPA.
  • This case highlights the importance of vigilant monitoring for opportunistic infections in immunocompromised hosts.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
317
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
998
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.5K